Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasper Tromp

Showing results (91-100 of 200) with videos related to

Pageof 20
Sort By:
JACC. Heart Failure|December 21, 2024
Clinical and Proteomic Risk Profiles of New-Onset Heart Failure in Men and WomenHailun Qin, Jasper Tromp, Jozine M Ter Maaten, et al.
European Journal of Heart Failure|October 5, 2022
Association of time-to-intravenous furosemide with mortality in acute heart failure: data from REPORT-HFWouter Ouwerkerk, Jasper Tromp, John G F Cleland, et al.
European Journal of Heart Failure|April 4, 2024
Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction - Results from the EMPULSE trialJasper Tromp, Mikhail N Kosiborod, Christiane E Angermann, et al.
European Journal of Heart Failure|February 20, 2021
Sodium-glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trialJasper Tromp, Piotr Ponikowski, Afshin Salsali, et al.
European Journal of Heart Failure|September 6, 2022
Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trialAdriaan A Voors, Kevin Damman, John R Teerlink, et al.
Cardiovascular Research|July 23, 2018
OPLAH ablation leads to accumulation of 5-oxoproline, oxidative stress, fibrosis, and elevated fillings pressures: a murine model for heart failure with a preserved ejection fractionAtze van der Pol, Andres Gil, Jasper Tromp, et al.
American Heart Journal|September 13, 2021
A global perspective of racial differences and outcomes in patients presenting with acute heart failureJasper Tromp, Wouter Ouwerkerk, John G F Cleland, et al.
European Journal of Heart Failure|October 20, 2018
Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF studyJoão Pedro Ferreira, Marco Metra, Ify Mordi, et al.
International Journal of Cardiology|September 21, 2024
Clinical and proteomic profiles of chronic kidney disease in heart failure with reduced and preserved ejection fractionGeert H D Voordes, Adriaan A Voors, Annabelle Hoegl, et al.
European Journal of Heart Failure|December 19, 2019
Association between body surface area and prescribed doses of guideline-directed medications among international patients with heart failure and reduced ejection fractionTiew-Hwa Katherine Teng, Lauren Cooper, Wan Ting Tay, et al.
Pageof 20

Showing results (91-100 of 200) with videos related to

Sort By:
Pageof 20
JACC. Heart Failure|December 21, 2024
Clinical and Proteomic Risk Profiles of New-Onset Heart Failure in Men and WomenHailun Qin, Jasper Tromp, Jozine M Ter Maaten, et al.
European Journal of Heart Failure|October 5, 2022
Association of time-to-intravenous furosemide with mortality in acute heart failure: data from REPORT-HFWouter Ouwerkerk, Jasper Tromp, John G F Cleland, et al.
European Journal of Heart Failure|April 4, 2024
Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction - Results from the EMPULSE trialJasper Tromp, Mikhail N Kosiborod, Christiane E Angermann, et al.
European Journal of Heart Failure|February 20, 2021
Sodium-glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trialJasper Tromp, Piotr Ponikowski, Afshin Salsali, et al.
European Journal of Heart Failure|September 6, 2022
Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trialAdriaan A Voors, Kevin Damman, John R Teerlink, et al.
Cardiovascular Research|July 23, 2018
OPLAH ablation leads to accumulation of 5-oxoproline, oxidative stress, fibrosis, and elevated fillings pressures: a murine model for heart failure with a preserved ejection fractionAtze van der Pol, Andres Gil, Jasper Tromp, et al.
American Heart Journal|September 13, 2021
A global perspective of racial differences and outcomes in patients presenting with acute heart failureJasper Tromp, Wouter Ouwerkerk, John G F Cleland, et al.
European Journal of Heart Failure|October 20, 2018
Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF studyJoão Pedro Ferreira, Marco Metra, Ify Mordi, et al.
International Journal of Cardiology|September 21, 2024
Clinical and proteomic profiles of chronic kidney disease in heart failure with reduced and preserved ejection fractionGeert H D Voordes, Adriaan A Voors, Annabelle Hoegl, et al.
European Journal of Heart Failure|December 19, 2019
Association between body surface area and prescribed doses of guideline-directed medications among international patients with heart failure and reduced ejection fractionTiew-Hwa Katherine Teng, Lauren Cooper, Wan Ting Tay, et al.
Pageof 20